KemPharm Shares Trade Higher After FDA Approval For Azstarys In ADHD

 

• The FDA has approved KemPharm Inc's (NASDAQ: KMPH) market application for Azstarys (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older.
• ADHD is a neurobehavioral disorder of childhood that makes it difficult for a person to pay attention and control impulsive behaviors.
• AZSTARYS consists of serdexmethylphenidate, KemPharm's prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.
• Azstarys will be commercially available in the U.S. as early as the second half of 2021.

https://www.benzinga.com/general/biotech/21/03/19978031/kempharm-shares-trade-higher-after-fda-approval-for-azstarys-in-adhd